Patents by Inventor Jacob Sten Petersen

Jacob Sten Petersen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES
    Publication number: 20190112348
    Abstract: Novel acylated insulin analogues exhibiting resistance towards proteases can, effectively, be administered pulmonary or orally. The insulin analogues contain B25H and A14E or A14H.
    Type: Application
    Filed: December 14, 2018
    Publication date: April 18, 2019
    Inventors: Peter Madsen, Thomas Boerglum Kjeldsen, Thomas Hoeg-Jensen, Palle Jakobsen, Tina Moeller Tagmose, Tine Glendorf, Janos Tibor Kodra, Patrick William Garibay, Jacob Sten Petersen
  • Protease stabilized acylated insulin analogues
    Patent number: 10259856
    Abstract: Novel acylated insulin analogues exhibiting resistance towards proteases can, effectively, be administered pulmonary or orally. The insulin analogues contain B25H and A14E or A14H.
    Type: Grant
    Filed: April 14, 2015
    Date of Patent: April 16, 2019
    Assignee: Novo Nordisk A/S
    Inventors: Peter Madsen, Thomas Boerglum Kjeldsen, Thomas Hoeg-Jensen, Palle Jakobsen, Tina Moeller Tagmose, Tine Glendorf, Janos Tibor Kodra, Patrick William Garibay, Jacob Sten Petersen
  • Use of NKG2D Inhibitors for Treating Cardiovascular and Metabolic Diseases, Such as Type 2 Diabetes
    Publication number: 20150376281
    Abstract: The present invention provides methods, compositions and kits for treating and detecting type 2 diabetes and/or conditions that may be regulated or normalised via inhibition of NKG2D, such as cardiovascular diseases.
    Type: Application
    Filed: September 10, 2015
    Publication date: December 31, 2015
    Inventors: Na Xiong, Mingcan Xia, David H. Raulet, Jacob Sten Petersen, Thora Brynja Bodvarsdottir
  • PROTEASE STABILIZED ACYLATED INSULIN ANALOGUES
    Publication number: 20150210748
    Abstract: Novel acylated insulin analogues exhibiting resistance towards proteases can, effectively, be administered pulmonary or orally. The insulin analogues contain B25H and A14E or A14H.
    Type: Application
    Filed: April 14, 2015
    Publication date: July 30, 2015
    Inventors: Peter Madsen, Thomas B. Kjeldsen, Thomas Hoeg-Jensen, Palle Jakobsen, Tina Moeller Tagmose, Tine Glendorf, Janos Tibor Kodra, Patrick William Garibay, Jacob Sten Petersen
  • PROTEASE STABILIZED ACYLATED INSULIN ANALOGUES
    Publication number: 20150210747
    Abstract: Novel acylated insulin analogues exhibiting resistance towards proteases can, effectively, be administered pulmonary or orally. The insulin analogues contain B25H and A14E or A14H.
    Type: Application
    Filed: April 13, 2015
    Publication date: July 30, 2015
    Inventors: Peter Madsen, Thomas B. Kjeldsen, Thomas Hoeg-Jensen, Palle Jakobsen, Tina Moeller Tagmose, Tine Glendorf, Janos Tibor Kodra, Patrick William Garibay, Jacob Sten Petersen
  • Protease stabilized, acylated insulin analogues
    Patent number: 9045560
    Abstract: Novel acylated insulin analogues exhibiting resistance towards proteases can, effectively, be administered pulmonary or orally. The insulin analogues contain B25H and A14E or A14H.
    Type: Grant
    Filed: August 22, 2013
    Date of Patent: June 2, 2015
    Assignee: NOVO NORDISK A/S
    Inventors: Peter Madsen, Thomas Boerglum Kjeldsen, Thomas Hoeg-Jensen, Palle Jakobsen, Tina Moeller Tagmose, Tine Glendorf, Jaanos Tibor Kodra, Patrick William Garibay, Jacob Sten Petersen
  • PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES
    Publication number: 20140073564
    Abstract: Novel acylated insulin analogues exhibiting resistance towards proteases can, effectively, be administered pulmonary or orally. The insulin analogues contain B25H and A14E or A14H.
    Type: Application
    Filed: August 22, 2013
    Publication date: March 13, 2014
    Applicant: Novo Nordisk A/S
    Inventors: Peter Madsen, Thomas Boerglum Kjeldsen, Thomas Hoeg-Jensen, Palle Jakobsen, Tina Moeller Tagmose, Tine Glendorf, Jaanos Tibor Kodra, Patrick William Garibay, Jacob Sten Petersen
  • USE OF NKG2D INHIBITORS FOR TREATING CARDIOVASCULAR AND METABOLIC DISEASES, SUCH AS TYPE 2 DIABETES
    Publication number: 20120148581
    Abstract: The present invention provides methods, compositions and kits for treating and detecting type 2 diabetes and/or conditions that may be regulated or normalised via inhibition of NKG2D, such as cardiovascular diseases.
    Type: Application
    Filed: August 16, 2010
    Publication date: June 14, 2012
    Applicants: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE PENN STATE RESEARCH FOUNDATION
    Inventors: Na Xiong, Mingcan Xia, David H. Raulet, Jacob Sten Petersen, Thora Brynja Bodvarsdottir
  • PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES
    Publication number: 20110105720
    Abstract: Novel acylated insulin analogues exhibiting resistance towards proteases can, effectively, be administered pulmonary or orally. The insulin analogues contain B25H and A14E or A14H.
    Type: Application
    Filed: March 13, 2009
    Publication date: May 5, 2011
    Inventors: Peter Madsen, Thomas Børglum Kjeldsen, Thomas Hoeg-Jensen, Palle Jakobsen, Tina Møller Tagmose, Tine Glendorf, Jånos Tibor Kodra, Patrick William Garibay, Jacob Sten Petersen
  • Methods for Treating Diabetes
    Publication number: 20090042781
    Abstract: Methods for treating diabetes by increasing the insulin secretion by administration of a GLP-1 receptor agonist and/or a DPP-IV inhibitor in combination with a proton pump inhibitor and optionally a PPAR agonist are provided.
    Type: Application
    Filed: June 23, 2005
    Publication date: February 12, 2009
    Applicant: Novo Nordisk A/S
    Inventors: Jacob Sten Petersen, Lars Hansen, Elisabeth D. Galsgaard
  • Combinations of antigen and mucosal binding component for inducing specific immunological tolerance
    Patent number: 7097845
    Abstract: This invention provides combinations of a tolerance-inducing antigen such as insulin and a mucosal binding component that preferably binds ganglioside GM1. The components are present in a non-covalent arrangement. When administered to a mucosal surface, the combinations are effective in inducing specific immunological tolerance at a 10-fold lower dose than antigen alone. Tolerance is sustained for a number of weeks without the necessity of booster administrations. The compositions and procedures of this invention are of benefit for the prevention or amelioration of conditions attributable to an unwanted immunological response.
    Type: Grant
    Filed: April 22, 1998
    Date of Patent: August 29, 2006
    Inventor: Jacob Sten Petersen
  • Inhibition of beta cell degeneration
    Publication number: 20030220251
    Abstract: This invention relates to a method for modulating, inhibiting or decreasing or preventing beta cell degeneration, loss of beta cell function, beta cell dysfunction, and/or death of beta cells, such as necrosis or apoptosis of beta cells in a subject comprising administering a GLP-1 agonist to said subject.
    Type: Application
    Filed: February 24, 2003
    Publication date: November 27, 2003
    Inventors: Liselotte Bjerre Knudsen, Carsten Foged Godtfredsen, Jacob Sten Petersen, Richard David Carr
  • Inhibition of beta cell degeneration
    Patent number: 6569832
    Abstract: This invention relates to a method for modulating, inhibiting or decreasing or preventing beta cell degeneration, loss of beta cell function, beta cell dysfunction, and/or death of beta cells, such as necrosis or apoptosis of beta cells in a subject comprising administering a GLP-1 agonist to said subject.
    Type: Grant
    Filed: November 10, 2000
    Date of Patent: May 27, 2003
    Assignee: Novo Nordisk A/S
    Inventors: Liselotte Bjerre Knudsen, Carsten Foged Godtfredsen, Jacob Sten Petersen, Richard David Carr, Søren Bregenholt
  • COMBINATIONS OF ANTIGEN AND MUCOSAL BINDING COMPONENT FOR INDUCING SPECIFIC IMMUNOLOGICAL TOLERANCE
    Publication number: 20020119159
    Abstract: This invention provides combinations of a tolerance-inducing antigen such as insulin and a mucosal binding component that preferably binds ganglioside GM 1. The components are present in a non-covalent arrangement. When administered to a mucosal surface, the combinations are effective in inducing specific immunological tolerance at a 10-fold lower dose than antigen alone. Tolerance is sustained for a number of weeks without the necessity of booster administrations. The compositions and procedures of this invention are of benefit for the prevention or amelioration of conditions attributable to an unwanted immunological response.
    Type: Application
    Filed: April 22, 1998
    Publication date: August 29, 2002
    Inventor: JACOB STEN PETERSEN